secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2026-08-10T20:35:21+00:00
Accession:  0001437749-26-026790
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Q2 loss $10.1M; PE trial shows 29.1 mmHg SBP drop
-----------------------------------------------------------

- Net loss $10.1M in Q2 2026 vs $7.7M Q2 2025; six-month loss $20.2M vs $15.4M.
- Cash $43.5M at June 30, 2026 vs $59.9M at Dec 31, 2025; runway through 2027.
- Phase 2 PE Part 1a: DM199 reduced SBP 29.1 mmHg (p<0.001) from 169.3 mmHg baseline; DBP 17.0 mmHg.
- FGR Phase 2 first cohort of 6 patients (5 µg/kg) fully enrolled; topline results due September.
- ReMEDy2 AIS trial enrollment >85% of 200 patients; interim analysis expected Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/0001437749-26-026790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/dmtp20260809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer